Skip to main content

Table 2 Clinical characteristics according to baseline eGFR

From: Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients

Patient Group H
6 (15%)
Group M
26 (65%)
Group L
8 (20%)
p-value
[background factors]
 Age, median [range] 53.5 [40–70] 66.5 [33–78] 73 [67–78] 0.0055
 Sex, male (%) 0 (0) 8 (30.8) 5 (62.5) 0.0206
 BW (kg), median [range] 50.5 [41.6–61] 58.0 [38.5–97.1] 61.5 [35.3–79.2] 0.1810
 Histopathology, follicular (%) 3 (50.0) 8 (30.8) 4 (50.0) 0.4916
 Performance status, ≥ 1 3 (50.0) 11 (42.3) 3 (37.5) 0.8959
 eGFR at baseline (mL/min/1.73 m2), median [range] 104.5 [92.8–119.1] 73.3 [60.4–88.7] 49.9 [43.6–58.3] < 0.0001
 Proteinuria grade 1 at baseline, yes (%) 0 (0) 2 (7.7) 0 (0) 0.4108
 Past hypertension history (%) 1 (16.7) 16 (61.5) 7 (87.5) 0.0207
 Past diabetes mellitus history (%) 1 (16.7) 1 (3.9) 1 (12.5) 0.4970
 Past renal history (%) 0 (0) 3 (11.5) 0 (0) 0.2574
 Renal metastasis, (%) 0 (0) 3 (11.5) 0 (0) 0.4108
 Liver metastasis, (%) 0 (0) 6 (23.1) 1 (12.5) 0.2255
[treatment factors]
 Treatment period (months), [average] 38.1 ± 16.3 31.3 ± 16.8 29.1 ± 17.7 0.5434
 Observation period (months), [average] 46.2 ± 11.8 31.8 ± 15.2 25.7 ± 15.0 0.0431
 Dose Intensity, median [average] 10.2 ± 2.0 9.4 ± 3.0 10.4 ± 3.5 0.6515
 Best response in RECIST criteria, PR (%) 6 (100) 20 (77) 3 (38) 0.0463
 Proteinuria grade 3, yes (%) 5 (83) 14 (54) 2 (25) 0.0914
 Treatment continuation, yes (%) 3 (50) 10 (38) 4 (50) 0.7812
 Treatment termination due to renal problem *, yes (%) 1 (17) 5 (19) 1 (13) 0.9020
  1. *: decline of eGFR or uncontrollable proteinuria